These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 27830036)
1. Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis [Retraction]. Am J Transl Res; 2016; 8(10):4510. PubMed ID: 27830036 [TBL] [Abstract][Full Text] [Related]
2. Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. Wang Y; Li L; Wang Y; Tang SN; Zheng W Am J Transl Res; 2015; 7(10):2082-90. PubMed ID: 26692952 [TBL] [Abstract][Full Text] [Related]
3. Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis. Wang Y; Li L; Wang Y; Tang SN; Zheng W Am J Transl Res; 2016; 8(1):230-8. PubMed ID: 27069556 [TBL] [Abstract][Full Text] [Related]
4. Secretory cell expansion with aging: risk for pelvic serous carcinogenesis. Li J; Ning Y; Abushahin N; Yuan Z; Wang Y; Wang Y; Yuan B; Cragun JM; Chambers SK; Hatch K; Kong B; Zheng W Gynecol Oncol; 2013 Dec; 131(3):555-60. PubMed ID: 24060413 [TBL] [Abstract][Full Text] [Related]
5. [Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas]. Asaturova AV; Ezhova LS; Faizullina NM; Adamyan LV; Khabas GN; Sannikova MV Arkh Patol; 2017; 79(3):10-18. PubMed ID: 28631711 [TBL] [Abstract][Full Text] [Related]
6. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838 [TBL] [Abstract][Full Text] [Related]
7. Retraction note to four articles published in Cui Q World J Orthop; 2018 Mar; 9(3):58-59. PubMed ID: 29564215 [TBL] [Abstract][Full Text] [Related]
8. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
9. [Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum]. Šišovská I; Minář L; Felsinger M; Anton M; Bednaříková M; Hausnerová J; Jandáková E; Weinberger V Ceska Gynekol; 2017; 82(3):230-236. PubMed ID: 28593778 [TBL] [Abstract][Full Text] [Related]
10. [The Fallopian tube odyssey: from the ovary to the tube. About high-grade serous ovarian carcinoma]. Chêne G; Dauplat J; Radosevic-Robin N; Cayre A; Penault-Llorca F Bull Cancer; 2013; 100(7-8):757-64. PubMed ID: 23831931 [TBL] [Abstract][Full Text] [Related]
11. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma]. Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294 [No Abstract] [Full Text] [Related]
12. Mucosal Proliferations in Completely Examined Fallopian Tubes Accompanying Ovarian Low-grade Serous Tumors: Neoplastic Precursor Lesions or Normal Variants of Benign Mucosa? Wolsky RJ; Price MA; Zaloudek CJ; Rabban JT Int J Gynecol Pathol; 2018 May; 37(3):262-274. PubMed ID: 28700429 [TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of γ-H2AX and p53 nuclear expression levels in ovarian and fallopian tube epithelium from risk-reducing salpingo-oophorectomies in BRCA1 and BRCA2 mutation carriers. Staff S; Tolonen T; Laasanen SL; Mecklin JP; Isola J; Mäenpää J Int J Gynecol Pathol; 2014 May; 33(3):309-16. PubMed ID: 24681744 [TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. Qiu C; Lu N; Wang X; Zhang Q; Yuan C; Yan S; Dongol S; Li Y; Sun X; Sun C; Zhang Z; Zheng W; Kong B Gynecol Oncol; 2017 Dec; 147(3):634-641. PubMed ID: 28965696 [TBL] [Abstract][Full Text] [Related]
15. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US. Liao CI; Chow S; Chen LM; Kapp DS; Mann A; Chan JK Gynecol Oncol; 2018 May; 149(2):318-323. PubMed ID: 29514737 [TBL] [Abstract][Full Text] [Related]
16. [Fallopian tube: the dark face of pelvic carcinogenesis]. Watkin E; Devouassoux-Shisheboran M Ann Pathol; 2011 Oct; 31(5):345-52. PubMed ID: 21982240 [TBL] [Abstract][Full Text] [Related]
18. Serous carcinogenesis in the fallopian tube: a descriptive classification. Jarboe E; Folkins A; Nucci MR; Kindelberger D; Drapkin R; Miron A; Lee Y; Crum CP Int J Gynecol Pathol; 2008 Jan; 27(1):1-9. PubMed ID: 18156967 [TBL] [Abstract][Full Text] [Related]
19. Transferrin facilitates the formation of DNA double-strand breaks via transferrin receptor 1: the possible involvement of transferrin in carcinogenesis of high-grade serous ovarian cancer. Shigeta S; Toyoshima M; Kitatani K; Ishibashi M; Usui T; Yaegashi N Oncogene; 2016 Jul; 35(27):3577-86. PubMed ID: 26549031 [TBL] [Abstract][Full Text] [Related]
20. [Morphologic changes of fallopian tubal epithelium in ovarian serous tumors]. Wen J; Shi JL; Shen DH; Chen YX; Song QJ Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):433-7. PubMed ID: 22932451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]